Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Get Free Report) had its price objective boosted by equities researchers at HC Wainwright from $8.00 to $21.00 in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 307.77% from the stock’s current price. HC Wainwright also issued estimates for Neuphoria Therapeutics Inc. – Common Stock’s FY2027 earnings at ($1.21) EPS and FY2028 earnings at ($1.36) EPS.
Neuphoria Therapeutics Inc. – Common Stock Price Performance
Shares of NASDAQ NEUP opened at $5.15 on Tuesday. Neuphoria Therapeutics Inc. – Common Stock has a 52-week low of $2.12 and a 52-week high of $16.08.
About Neuphoria Therapeutics Inc. – Common Stock
Featured Articles
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- How to Invest in the FAANG Stocks
- 3 Must-Have ETFs Set to Dominate This Quarter
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
